Literature DB >> 6428022

Management of newly diagnosed metastatic carcinoma of the prostate.

J S Elder, W J Catalona.   

Abstract

Metastatic prostatic cancer can be present in a variety of different ways. The authors describe the differences among stages D-0, D-1, and D-2 disease and present the treatment options for each of the substages. They summarize and integrate the clinical evidence that bears on the potential efficacy of each treatment.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6428022

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  2 in total

1.  Advances in the treatment of metastatic prostatic cancer.

Authors:  J S Elder; R P Gibbons
Journal:  West J Med       Date:  1985-09

2.  Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer.

Authors:  T Kylmälä; T L Tammela; L Risteli; J Risteli; M Kontturi; I Elomaa
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.